There have been reports of noninfectious pneumonitis (including some with pulmonary hypertension as a secondary event), infections, and renal failure (including acute renal failure) in patients...
$0 Universal Co-Pay Card
At Novartis Oncology, we’ve made it easier for patients to access co-pay assistance on their prescription costs for almost all Novartis Oncology products. Patients may be eligible for immediate co-pay savings on their next prescription:
Limitations apply. Offer is not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice.
Encourage your patients to find out if they are eligible to enroll in the Universal Co-pay Program by visiting www.CoPay.NovartisOncology.com or calling 1-877-577-7756.
Terms and Conditions
This offer is valid only for those with commercial insurance. Offer not valid under Medicare, Medicaid, or any other federal or state program. Not valid for cash-paying patients, where product is not covered by patient’s commercial insurance, or where plan reimburses you for entire cost of your prescription drug. Offer is not valid where prohibited by law. Valid only in the United States and Puerto Rico. This program is not health insurance. Offer may not be combined with any other rebate, coupon, or offer. The card is the property of Novartis Pharmaceuticals Corporation and must be returned upon request. Novartis reserves the right to rescind, revoke, or amend the program without notice. Patient certifies responsibility for complying with applicable limitations, if any, of any commercial insurance and reporting receipt of program rewards, if necessary, to any commercial insurer. This offer expires on December 31, 2018.
The AFINITOR 14-Day Free Trial helps eligible patients start therapy quickly. A 14-day supply is shipped directly to a patient’s home or another convenient location. This one-time trial is available to all patients prescribed AFINITOR for a US Food and Drug Administration (FDA)-approved indication without regard to purchase of AFINITOR or any other product.
To find the Novartis Oncology Service Request Form, click or visit
Novartis Oncology shares your commitment to helping patients receive the medicines they need. Patient Assistance Now Oncology (PANO) provides access to information and our wide range of resources available to your patients in over 160 languages.
Support for patients includes:
To learn more, call 1-800-282-7630.
AFINITOR is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.
Important Safety Information
AFINITOR is contraindicated in patients with clinically significant hypersensitivity to everolimus or to other rapamycin derivatives.
Severe Hypersensitivity Reactions
Angioedema With Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors
Impaired Wound Healing
Risk of Infection or Reduced Immune Response With Vaccinations
Please see full Prescribing Information.